Cargando…

PCSK9 Inhibitors in a Statin-Intolerant Transgender Man With Heterozygous Familial Hypercholesterolemia: A Case Report

In female-to-male transgender individuals, testosterone is used to induce masculinization. Sex steroid therapy may increase circulating triglyceride and low-density lipoprotein cholesterol (LDL-C) levels and may decrease high-density lipoprotein cholesterol (HDL-C) levels, resulting in a more athero...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pirazzi, Carlo, Tavaglione, Federica, Tivesten, Åsa, Romeo, Stefano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Endocrine Society 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6665951/ https://www.ncbi.nlm.nih.gov/pubmed/31380502 http://dx.doi.org/10.1210/js.2019-00070

Ejemplares similares

Elevated PCSK9 Levels in Untreated Patients With Heterozygous or Homozygous Familial Hypercholesterolemia and the Response to High‐Dose Statin Therapy
por: Raal, Frederick, et al.
Publicado: (2013)

Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: patient selection and perspectives
por: Catapano, Alberico Luigi, et al.
Publicado: (2017)

Therapeutic efficacy and safety of PCSK9-monoclonal antibodies on familial hypercholesterolemia and statin-intolerant patients: A meta-analysis of 15 randomized controlled trials
por: Qian, Li Jun, et al.
Publicado: (2017)

May statins and PCSK9 inhibitors be protective from COVID-19 in familial hypercholesterolemia subjects?
por: Scicali, Roberto, et al.
Publicado: (2020)

Use of PCSK9 Inhibitor in a Mexican Boy with Compound Heterozygous Familial Hypercholesterolemia: A Case Report
por: Ceballos-Macías, José Juan, et al.
Publicado: (2019)

Patients With LDLR and PCSK9 Gene Variants Experienced Higher Incidence of Cardiovascular Outcomes in Heterozygous Familial Hypercholesterolemia
por: Doi, Takahito, et al.
Publicado: (2021)

PCSK9 Antibodies for the Treatment of Hypercholesterolemia
por: Gouni-Berthold, Ioanna, et al.
Publicado: (2014)

Role of PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia
por: Tomlinson, Brian, et al.
Publicado: (2021)

Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance
por: Laufs, Ulrich, et al.
Publicado: (2019)

Budget Impact Analysis of PCSK9 Inhibitors for the Management of Adult Patients with Heterozygous Familial Hypercholesterolemia or Clinical Atherosclerotic Cardiovascular Disease
por: Mallya, Usha G., et al.
Publicado: (2017)

Coronary Artery Plaque Regression by a PCSK9 Antibody and Rosuvastatin in Double-heterozygous Familial Hypercholesterolemia with an LDL Receptor Mutation and a PCSK9 V4I Mutation
por: Shirahama, Ryo, et al.
Publicado: (2018)

PCSK9 Variants in Familial Hypercholesterolemia: A Comprehensive Synopsis
por: Guo, Qianyun, et al.
Publicado: (2020)

Cataract Surgery in Elderly Subjects with Heterozygous Familial Hypercholesterolemia in Prolonged Treatment with Statins
por: Marco-Benedí, Victoria, et al.
Publicado: (2021)

Antiplatelet Effects of PCSK9 Inhibitors in Primary Hypercholesterolemia
por: Pęczek, Piotr, et al.
Publicado: (2021)

LDL‐cholesterol and PCSK9 in patients with familial hypercholesterolemia: influence of PCSK9 variants under lipid‐lowering therapy
por: Hamasaki, Masato, et al.
Publicado: (2021)

Real-World Efficacy of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Heterozygous Familial Hypercholesterolemia Patients Referred for Lipoprotein Apheresis
por: Matta, Anthony, et al.
Publicado: (2021)

The LDLR, APOB, and PCSK9 Variants of Index Patients with Familial Hypercholesterolemia in Russia
por: Meshkov, Alexey, et al.
Publicado: (2021)

PCSK9 Inhibition With Monoclonal Antibodies: Modern Management of Hypercholesterolemia
por: Ito, Matthew K., et al.
Publicado: (2016)

Effect of PCSK9 Inhibitors on Hemostasis in Patients with Isolated Hypercholesterolemia
por: Basiak, Marcin, et al.
Publicado: (2022)

Monoclonal Antibodies in the Management of Familial Hypercholesterolemia: Focus on PCSK9 and ANGPTL3 Inhibitors
por: Pirillo, Angela, et al.
Publicado: (2021)

Diagnosis and Treatment of Heterozygous Familial Hypercholesterolemia
por: McGowan, Mary P., et al.
Publicado: (2019)

Effect of LDL cholesterol, statins and presence of mutations on the prevalence of type 2 diabetes in heterozygous familial hypercholesterolemia
por: Climent, Elisenda, et al.
Publicado: (2017)

microRNA-483 ameliorates hypercholesterolemia by inhibiting PCSK9 production
por: Dong, Jianjie, et al.
Publicado: (2020)

PCSK9 Inhibitors for the Management of Mitotane-Induced Hypercholesterolemia in Adrenocortical Carcinoma
por: Aurora, John A, et al.
Publicado: (2021)

Low-density lipoprotein cholesterol outcomes post-non-PCSK9i lipid-lowering therapies in atherosclerotic cardiovascular disease and probable heterozygous familial hypercholesterolemia patients
por: Chen, Chi-Chang, et al.
Publicado: (2018)

Achilles Tendon Xanthoma Thickness and Carotid Intima-Media Thickness in a Patient With Heterozygous Familial Hypercholesterolemia on PCSK9 Inhibition: A Case Report and Literature Review
por: Alam, Loba, et al.
Publicado: (2020)

Efficacy and Safety of PCSK9 Inhibitors in Hypercholesterolemia Associated With Refractory Nephrotic Syndrome
por: Jatem, Elias, et al.
Publicado: (2020)

PCSK9 immunization using nanoliposomes: preventive efficacy against hypercholesterolemia and atherosclerosis
por: Momtazi-Borojeni, Amir Abbas, et al.
Publicado: (2021)

Genetic screening for homozygous and heterozygous familial hypercholesterolemia
por: Izar, Maria C, et al.
Publicado: (2010)

Pharmacological Strategies beyond Statins: Ezetimibe and PCSK9 Inhibitors
por: Choi, Jah Yeon, et al.
Publicado: (2019)

Association of PCSK9 Inhibitor Initiation on Statin Adherence and Discontinuation
por: LaFratte, Christopher, et al.
Publicado: (2023)

PCSK9 inhibitor recaticimab for hypercholesterolemia on stable statin dose: a randomized, double-blind, placebo-controlled phase 1b/2 study
por: Xu, Mingtong, et al.
Publicado: (2022)

Statin Intolerance and Suboptimal Statin Therapy
por: Tada, Hayato, et al.
Publicado: (2019)

Comparative quantitative systems pharmacology modeling of anti-PCSK9 therapeutic modalities in hypercholesterolemia
por: Sokolov, Victor, et al.
Publicado: (2019)

The PCSK9 discovery, an inactive protease with varied functions in hypercholesterolemia, viral infections, and cancer
por: Seidah, Nabil G.
Publicado: (2021)

Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody
por: Hopkins, Paul N., et al.
Publicado: (2015)

Plasma PCSK9 levels are significantly modified by statins and fibrates in humans
por: Mayne, Janice, et al.
Publicado: (2008)

Metabolomic Consequences of Genetic Inhibition of PCSK9 Compared With Statin Treatment
por: Sliz, Eeva, et al.
Publicado: (2018)

Statins and PCSK9 inhibitors: What is their role in coronavirus disease 2019?
por: Barkas, Fotios, et al.
Publicado: (2021)

Hepatocellular carcinoma-associated hypercholesterolemia: involvement of proprotein-convertase-subtilisin-kexin type-9 (PCSK9)
por: Athavale, Dipti, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_4av9659l2rdcse0sd9juapfnf4